Bacterial biofilm infections of implantable medical devices decrease the effectiveness of antibiotics, creating difficult-to-treat chronic infections. Prosthetic joint infections (PJI) are particularly problematic because they require prolonged antibiotic courses and reoperations to remove and replace the infected prostheses. Current models to study PJI focus on Gram-positive bacteria, but Gram-negative PJI (GN-PJI) are increasingly common and are often more difficult to treat, with worse clinical outcomes. Herein, we sought to develop a mouse model of GN-PJI to investigate the pathogenesis of these infections and identify potential therapeutic targets. An orthopedic-grade titanium implant was surgically placed in the femurs of mice, followed by infection of the knee joint with *Pseudomonas aeruginosa* or *Escherichia coli*. We found that in vitro biofilm-producing activity was associated with the development of an in vivo orthopedic implant infection characterized by bacterial infection of the bone/joint tissue, biofilm formation on the implants, reactive bone changes, and inflammatory immune cell infiltrates. In addition, a bispecific antibody targeting *P. aeruginosa* virulence factors (PcrV and Psl exopolysaccharide) reduced the bacterial burden in vivo. Taken together, our findings provide a preclinical model of GN-PJI and suggest the therapeutic potential of targeting biofilm-associated antigens.
Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets

John M. Thompson,1 Robert J. Miller,2 Alyssa G. Ashbaugh,2 Carly A. Dillen,2 Julie E. Pickett,3 Yu Wang,2 Roger V. Ortines,2 Robert S. Sterling,1 Kevin P. Francis,4,5 Nicholas M. Bernthal,5 Taylor S. Cohen,6 Christine Tkaczyk,6 Li Yu,7 C. Kendall Stover,6 Antonio DiGiandomenico,6 Bret R. Sellman,6 Daniel L.J. Thorek,3,8 and Lloyd S. Miller1,2,9,10

1Department of Orthopaedic Surgery, 2Department of Dermatology, and 3Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4PerkinElmer, Hopkinton, Massachusetts, USA. 5Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Santa Monica, California, USA. 6Department of Infectious Diseases and 7Statistical Sciences, MedImmune, Gaithersburg, Maryland, USA. 8Cancer Molecular and Functional Imaging Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, and 9Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 10Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Bacterial biofilm infections of implantable medical devices decrease the effectiveness of antibiotics, creating difficult-to-treat chronic infections. Prosthetic joint infections (PJI) are particularly problematic because they require prolonged antibiotic courses and reoperations to remove and replace the infected prostheses. Current models to study PJI focus on Gram-positive bacteria, but Gram-negative PJI (GN-PJI) are increasingly common and are often more difficult to treat, with worse clinical outcomes. Herein, we sought to develop a mouse model of GN-PJI to investigate the pathogenesis of these infections and identify potential therapeutic targets. An orthopedic-grade titanium implant was surgically placed in the femurs of mice, followed by infection of the knee joint with Pseudomonas aeruginosa or Escherichia coli. We found that in vitro biofilm-producing activity was associated with the development of an in vivo orthopedic implant infection characterized by bacterial infection of the bone/joint tissue, biofilm formation on the implants, reactive bone changes, and inflammatory immune cell infiltrates. In addition, a bispecific antibody targeting P. aeruginosa virulence factors (PcrV and Psl exopolysaccharide) reduced the bacterial burden in vivo. Taken together, our findings provide a preclinical model of GN-PJI and suggest the therapeutic potential of targeting biofilm-associated antigens.

Introduction

Gram-negative (GN) prosthetic joint infections (PJI) represent an important and emerging clinical problem, but their pathogenesis is poorly understood. Historically, GN-PJI were considered a rare complication, accounting for 3%–6% of all PJI (1–3). However, during the past 15 years, reports from around the world have uncovered much higher rates of GN-PJI, ranging between 15 and 36 percent of all PJI (4–9). Pseudomonas aeruginosa and Escherichia coli were the most commonly reported infecting-organisms, and many cases were polymicrobial. As the number of primary and revision arthroplasties is projected to rise, the bacterial burden in vivo. Taken together, our findings provide a preclinical model of GN-PJI and suggest the therapeutic potential of targeting biofilm-associated antigens.
Results

Development of a mouse model of GN-PJI. To study the pathogenesis of a GN-PJI, we modified a previously described model of a GP-PJI (30–32). This was accomplished by surgically placing an orthopedic-grade titanium Kirschner-wire into the right femurs of C57BL/6 mice, with the end protruding into the knee joint, followed by bacterial inoculation before closure. We first performed experiments to determine the optimal inoculum for each bacterium by evaluating 3 different inocula (1 × 10³, 1 × 10⁴, and 1 × 10⁵ CFU) of bioluminescent P. aeruginosa (Xen41) or E. coli (Xen14) strains that were pipetted into the exposed knee joints. The specific P. aeruginosa (Xen41) or E. coli (Xen14) strains used were previously reported to have biofilm-producing activity in vitro (33). To noninvasively monitor the in vivo bacterial burden, in vivo bioluminescence imaging (BLI) signals were measured on days 0, 1, 3, 7, 14, and 21 days, and ex vivo CFU were enumerated on bone/joint tissue and implants harvested on day 21, as previously described (31, 32). For P. aeruginosa, the 1 × 10⁴ CFU inoculum was chosen for subsequent experiments because the in vivo BLI signals were present for the entire 21-day course of infection, and there was no mortality (Supplemental Figures 1 and 2; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.121737DS1). In contrast, for P. aeruginosa, the 1 × 10³ CFU inoculum resulted in in vivo BLI signals that decreased close to background levels before the end of the experiment on day 21, and the 1 × 10⁵ CFU inoculum resulted in mortality in some of the mice. For E. coli, the 1 × 10³ CFU inoculum was chosen to be used in subsequent experiments because the in vivo BLI signals were present for the entire 21-day course of infection, and there was no mortality observed. In contrast, the 1 × 10³ or 1 × 10⁴ CFU inocula for E. coli resulted in clearance of the infection by day 21 in all mice, as determined by in vivo BLI signals and ex vivo CFU counting.

In vivo and ex vivo bacterial burden in GN-PJI. For P. aeruginosa, the in vivo BLI signals of the 1 × 10⁴ CFU inoculum peaked on day 3 (9.5 × 10⁴ ± 2.2 × 10⁴ photons/s/cm²/steradian) and decreased thereafter to a level that was statistically greater than the signals of uninfected control (sham surgery) mice and remained approximately a log above the background limit of detection (LOD) (Figure 1, A and B). For E. coli, the in vivo BLI signals of the 1 × 10⁵ CFU inoculum peaked on day 1 (9.5 × 10⁴ ± 3.3 × 10⁴ photons/s/cm²/steradian), which was similar to the peak signal intensity observed with P. aeruginosa and decreased to a level that was statistically greater than the signals of uninfected control mice, but they were only about a half-log above the LOD. Over the course of the experiment, the in vivo BLI signals of P. aeruginosa were statistically greater than the signals of E. coli. In vivo BLI signals of uninfected control mice remained below the LOD for the entire experiment. On day 21, mice were euthanized, and knee bone/joint tissues and implants were harvested to enumerate CFU from the tissue and sonicated implants. P. aeruginosa–infected mice had a mean of 3.3 × 10⁵ ± 0.7 × 10⁵ CFU from tissue samples (with all having at least 1.3 × 10⁵ CFU) and a mean of 4.4 × 10³ ± 1.6 × 10³ CFU from the implants (Figure 1, C and D). In contrast, E. coli–infected mice had a mean of 3.1 × 10⁴ ± 2.7 × 10⁴ CFU from the tissue samples (with more than half of the mice having no detectable CFU) and no detectable CFU from the implants, both statistically lower than the tissue and implant CFU of P. aeruginosa–infected mice. Uninfected control mice had no detectable CFU from the tissue samples or implants.

To determine whether there were any remaining CFU, the tissue samples and implants were then cultured in shaking broth for an additional 48 hours followed by overnight culture on plates, and the presence or absence of bacterial growth was determined. For P. aeruginosa–infected mice, all 15 of 15 tissue samples and implants had bacterial growth. For E. coli–infected mice, 10 of 15 tissue samples (67%) and only 1 of 15 implants (7%) had bacterial growth; bacterial growth in both was significantly lower than the
presence of bacterial growth from the respective tissue samples and implants from *P. aeruginosa*–infected mice (Figure 1E). Uninfected control mice had no bacterial growth from the tissue samples or implants.

**Biofilm formation on implants in GN-PJI**. To evaluate for biofilm formation on the implants, day 21 implants were harvested and fixed for scanning electron microscopy. On implants from *P. aeruginosa*–infected mice, substantial biofilm formation was visualized on the intra-articular end of the implant, with the characteristic viscous fibers covering the metal surface as well as adherent host immune cells (Figure 1F). In comparison, implants from *E. coli*–infected or uninfected mice demonstrated only adherent host immune cells with no discernible biofilm formation, similar to the bare metal surface of an implant prior to implantation.

**Reactive bone changes and inflammation in GN-PJI**. In our prior work using a mouse model of GP-PJI, progression of the infection over time resulted in expansion of the distal femur due to chronic reactive bone remodeling (32). To evaluate for similar expansion of the distal femur in response to a GN-PJI, anteroposterior X-rays of the distal femur were obtained on day 21, and distal femoral width and area were measured (Figure 2A). The distal femoral width of *P. aeruginosa*–infected mice had a mean of 3.8 ± 0.2 mm, which was significantly greater than the femoral width of *E. coli*–infected (mean 3.1 ± 0.1 mm) and uninfected mice (mean 3.0 ± 0.1 mm) (Figure 2B). The distal femoral areas of *P. aeruginosa*–infected mice had a mean value of 17.3 ± 0.7 mm², which was significantly greater than the femoral areas of *E. coli*–infected (mean 15.5 ± 0.4 mm²) and uninfected mice (mean 14.1 ± 0.4 mm²). The slightly increased femoral width but not the femoral area of *E. coli*–infected mice was statistically greater than uninfected mice.

To further measure the degree of inflammation at the site of the GN-PJI, [*18F*-fluoro-deoxy-glucose ([*18F*-FDG)](https://doi.org/10.1172/jci.insight.121737) PET imaging was employed. Although [*18F*-FDG] is taken up by bacteria via glucose transporters (34), prior reports that compared sites of sterile inflammation with infection revealed very small differences, indicating that most of the [*18F*-FDG] signals are from host inflammatory cells, such as neutrophils.
and monocytes, which are highly metabolically active and consume large quantities of glucose (35–37). On day 21, in *P. aeruginosa*–infected mice, the [18F]-FDG percent activity per gram of tissue (0.88% ± 0.12%) was significantly and nearly 3-fold higher than that of *E. coli*–infected mice (0.28% ± 0.10%) and uninfected mice (0.36 ± 0.04%) (Figure 2, C and D). The [18F]-FDG percent activity per gram of tissue for *E. coli*–infected mice was not significantly different from uninfected mice. Taken together, *P. aeruginosa* induced more substantial bone expansion and inflammation at the infection site than *E. coli*.

Similarly, day 21 histology of *P. aeruginosa*–infected mice revealed marked reactive bone changes within the cortical bone and physis and expansion of the cortical width at the distal end of the femurs adjacent to the site of biofilm formation on the implants (Figure 3, A–C). In addition, there were increased inflammatory immune cell infiltrates in the joint tissue (indicative of septic arthritis) and especially in the bone marrow cavity surrounding the implant site (indicative of osteomyelitis) (Figure 3D). In contrast, *E. coli*–infected mice had less expansion of the distal femurs, with more intact dense cortical bone and fewer reactive changes of the physis, along with fewer inflammatory cells in the bone marrow cavity, more closely resembling the histologic findings in uninfected control mice.

**Inflammatory cell infiltrates in GN-PJI.** To evaluate the specific composition of the immune cell infiltrates in the joint tissue, flow cytometry was performed on homogenized joint tissue specimens, as previously described in a model of GP-PJI (38). *P. aeruginosa*–infected mice, *E. coli*–infected mice, and uninfected mice all had neutrophil (Ly6G + Ly6C−) numbers and percentages that were not significantly different from each other (Figure 4). However, *P. aeruginosa*–infected mice had increased numbers and percentages of monocytes (Ly6G + Ly6C+) and macrophages (CD11b+ F4/80+) compared with uninfected mice. In contrast, *E. coli*–infected mice had significantly increased numbers but not percentages of monocytes compared with uninfected mice. The numbers and percentages of macrophages in *E. coli*–infected mice were not statistically different from uninfected mice. These results suggest that by day 21 there was more of a chronic inflammatory response in the *P. aeruginosa*–infected mice, given that they had increased monocyte and macrophage infiltrates, while neutrophil infiltrates associated with acute infection and inflammation were similar among the groups. Overall, *E. coli* infection did not lead to a chronic inflammatory state. It should also be noted that, in this model of GN-PJI, we did not observe a population of Ly6G+Ly6C+ myeloid-derived suppressor cells (Figure 4A), which have been previously reported to occur in GP-PJI mouse models with *S. aureus* (38).
In vitro biofilm-producing activity corresponds to the development of GN-PJI in vivo. The results in Figures 1–4 indicate that there was increased bacterial burden, biofilm formation, reactive bone changes, and inflammation in \textit{P. aeruginosa}–infected mice compared with \textit{E. coli}–infected mice, suggesting that \textit{P. aeruginosa} was more virulent in this mouse model of GN-PJI. However, \textit{E. coli} basically did not cause a productive infection in this GN-PJI. These results were somewhat unexpected because both \textit{P. aeruginosa} and \textit{E. coli} are the most common GN bacteria that cause PJI in humans (4–9). Although a prior report employed the same bioluminescent \textit{P. aeruginosa} (Xen41) and \textit{E. coli} (Xen14) strains used in this study in in vitro biofilm assays and indicated that both strains induced biofilms (33), we decided to directly quantify and compare the biofilm-producing activity of these strains as well as additional \textit{E. coli} strains. An established in vitro biofilm assay was performed as previously described (39). The additional \textit{E. coli} strains that we evaluated were the well-characterized reference strains 25922 and K12, as well as strain 836, a randomly chosen ESBL-producing strain from a patient with a urinary tract infection at the Johns Hopkins Hospital in 2013 (40). \textit{P. aeruginosa} strain Xen41 had significantly increased in vitro biofilm formation compared with all of the \textit{E. coli} strains (Figure 5A). However, among the \textit{E. coli} strains, strain 25922 had mean values for femoral width (mean 4.0 ± 0.1 mm) and area (mean 18.0 ± 0.6 mm$^2$) by X-ray.
analysis that were significantly greater compared with uninfected mice (Figure 5, E and F) as well as readily detectable biofilm formation on the implants (Figure 5G). Taken together, the enhanced in vitro biofilm-producing activity of *E. coli* strain 25922 led to a much more robust GN-PJI in vivo than *E. coli* strain Xen14. In addition, all of these results with *E. coli* strain 25922 closely resembled those observed in the *P. aeruginosa*-infected mice (Figures 1 and 2).

**Bispecific antibody targeting PcrV and Psl reduces *P. aeruginosa* GN-PJI in vivo.** Since increased in vitro biofilm forming activity was associated with more productive infections in the in vivo mouse model of GN-PJI for both *P. aeruginosa* and *E. coli*, we hypothesized that targeted inhibition of bacterial mechanisms involved in biofilm production would offer a therapeutic benefit. Therefore, we evaluated the potential prophylactic therapeutic effect of a bispecific antibody (MEDI3902) targeting two biofilm-associated virulence factors of *P. aeruginosa*: (a) PcrV, a protein produced by the type III secretion system of *P. aeruginosa* bacteria that is associated with bacterial aggregation that facilitates biofilm formation (29, 41), and (b) an exopolysaccharide involved in biofilm formation and maintenance (41, 42). Of note, MEDI3902 had previously been shown to be highly effective in promoting *P. aeruginosa* bacterial clearance in mouse models of lung infection, thermal injury, and bacteremia (26, 43, 44). Furthermore, incubation of established *P. aeruginosa* biofilms in vitro with a monoclonal antibody targeting Psl along with exogenous human neutrophils resulted in disruption and clearance of bacteria from *P. aeruginosa* biofilms (45). However, to the best of our knowledge, whether antibody-mediated targeting of PcrV and Psl results in a therapeutic benefit during an in vivo implant-related biofilm infection is unknown.

Mice were treated prophylactically via retro-orbital vein injection with MEDI3902 or an isotype control antibody (Control Ab) prior to performing the *P. aeruginosa* in vivo mouse PJI model. Compared with the Control Ab, MEDI3902 resulted in a diminished infection, as indicated by significantly decreased in vivo BLI signals (Figure 6A) and ex vivo CFU isolated from the tissue and implants (Figure 6, B and C). The Control Ab was
also compared with a sham injection of PBS (saline), and there were no significant differences in the in vivo BLI signals or ex vivo CFU from the tissue and implants (Supplemental Figure 3). Finally, to determine whether the antibodies accumulated at the site of infection, antibody levels of the MEDI3902 or the isotype Control Ab were measured in the bone/joint tissue homogenates at the end of the experiment on day 5. Both MEDI3902 and the isotype Control Ab accumulated at appreciable levels in the infected bone/joint tissue, which is consistent with the accumulation of antibodies at sites of inflammation and infection (46). However, there were lower levels of MEDI3902 than isotype Control Ab (Figure 6D), suggesting that MEDI3902 antibody bound to *P. aeruginosa* was cleared along with the bacteria in the treated mice.

**Discussion**

Increased understanding of the pathogenesis of GN-PJI to provide improved diagnostic and treatment options requires a reliable preclinical model. However, the only existing models in the literature to the best of our knowledge are those of GP-PJI (15, 16). Due to the many differences between virulence mechanisms and host-microbe interactions between GP and GN bacteria resulting in arguably fundamentally distinct types of infection (17–23), we sought to develop, characterize, and evaluate potential therapeutic targets in a preclinical mouse model of GN-PJI. We modified a previously described model of a GP-PJI (31, 32) in which an orthopedic-grade titanium Kirschner-wire was surgically placed in the femurs of mice followed by inoculation with *P. aeruginosa* or *E. coli* into the knee joint prior to closure. These GN bacteria were chosen since they represent more and less virulent causative pathogens, respectively, for GN-PJI in humans (4–9). In particular, we used the well-described bioluminescent *P. aeruginosa* Xen41 and *E. coli* Xen14 strains, as both had previously been reported to produce biofilms in vitro (33). Using this model, we uncovered several insights into the pathogenesis of GN-PJI.
In addition, it is possible that the virulence of the pathogen also influenced local development and severity in the in vivo GN-PJI model, which might also be a useful determinant to guide clinical treatment.

indicating that the in vitro biofilm-forming activity of \( P \)\textsubscript{E}\textsubscript{coli} provides a potential explanation for why \( P \)\textsubscript{E}\textsubscript{aeruginosa} Xen41 produced a more robust infection than \( P \)\textsubscript{E}\textsubscript{coli} strains Xen14, K12, and 836 exhibited a substantially lower ability to form in vitro biofilms. These data producing activity among the strains.

In a study to evaluate the efficacy of a salicylic acid–releasing catheter coating in inhibiting in vitro biofilms, but to produce the in vivo GN-PJI. Of note, the prevalence of \( E \)\textsubscript{coli} implants, and no biofilm formation visualized on the implants. This result was somewhat surprising given the prevalence of \( E \)\textsubscript{coli} as a pathogen for human GN-PJI (4–9). However, there might have been different biofilm-producing activity between \( P \)\textsubscript{aeruginosa} Xen41 and \( E \)\textsubscript{coli} Xen14 that could have affected the ability to produce the in vivo GN-PJI. Of note, \( P \)\textsubscript{aeruginosa} Xen41 and \( E \)\textsubscript{coli} Xen14 were both used in a single prior study to evaluate the efficacy of a salicylic acid–releasing catheter coating in inhibiting in vitro biofilms, but the relative biofilm-producing activities of Xen14 and Xen41 were not directly compared with each other (33).

First, \( P \)\textsubscript{aeruginosa} Xen41 was more virulent than \( E \)\textsubscript{coli} Xen14 in the in vivo PJI model because \( P \)\textsubscript{aeruginosa} (but not \( E \)\textsubscript{coli}) resulted in mortality in a small fraction of the mice (Supplemental Figure 2). Therefore, the \( P \)\textsubscript{aeruginosa} Xen41 strain was used at a log lower inoculum (1 × 10\textsuperscript{4} CFU) than \( E \)\textsubscript{coli} Xen14 (1 × 10\textsuperscript{6} CFU). However, despite the lower inoculum, \( P \)\textsubscript{aeruginosa} Xen41 resulted in greater bacterial burden in vivo and ex vivo, reactive bone changes, and inflammation at the site of infection than \( E \)\textsubscript{coli} Xen14. Upon further study, \( E \)\textsubscript{coli} strain Xen14 did not induce a productive biofilm infection in vivo, as there was no detectable ex vivo CFU isolated in half of the tissue samples, no bacterial growth from any of the cultured ex vivo implants, and no biofilm formation visualized on the implants. This result was somewhat surprising given the prevalence of \( E \)\textsubscript{coli} as a pathogen for human GN-PJI (4–9). However, there might have been different biofilm-producing activity between \( P \)\textsubscript{aeruginosa} Xen41 and \( E \)\textsubscript{coli} Xen14 that could have affected the ability to produce the in vivo GN-PJI. Of note, \( P \)\textsubscript{aeruginosa} Xen41 and \( E \)\textsubscript{coli} Xen14 were both used in a single prior study to evaluate the efficacy of a salicylic acid–releasing catheter coating in inhibiting in vitro biofilms, but the relative biofilm-producing activities of Xen14 and Xen41 were not directly compared with each other (33).

Second, in directly evaluating the in vitro biofilm-forming activity of \( P \)\textsubscript{aeruginosa} Xen41 and \( E \)\textsubscript{coli} Xen14 as well as 3 other \( E \)\textsubscript{coli} strains (25922 and K12 reference strains and the ESBL-producing strain 836, ref. 40) in an established in vitro microtiter biofilm assay (39), we found a broad range of biofilm-producing activity between the strains. \( P \)\textsubscript{aeruginosa} and \( E \)\textsubscript{coli} strain 25922 had the highest, whereas \( E \)\textsubscript{coli} strains Xen14, K12, and 836 exhibited a substantially lower ability to form in vitro biofilms. These data provide a potential explanation for why \( P \)\textsubscript{aeruginosa} Xen41 produced a more robust infection than \( E \)\textsubscript{coli} strain Xen14 in our in vivo GN-PJI model.

Third, if biofilm-forming activity was a major factor for the development of a GN-PJI in vivo, we reasoned that \( E \)\textsubscript{coli} strain 25922 would induce a more productive infection in this in vivo GN-PJI model. Indeed, \( E \)\textsubscript{coli} strain 25922 resulted in increased ex vivo CFU from tissue samples and implants with marked reactive bone changes and readily visualized biofilm formation on the implants. These findings closely resembled the degree of infection in the in vivo GN-PJI infection with \( P \)\textsubscript{aeruginosa} Xen41. Taken together, these data indicate that the in vitro biofilm-forming activity of \( P \)\textsubscript{aeruginosa} and \( E \)\textsubscript{coli} predicted virulence and disease severity in the in vivo GN-PJI model, which might also be a useful determinant to guide clinical treatment decisions. In addition, it is possible that the virulence of the pathogen also influenced local development and

Figure 6. Targeting PcrV and Psl reduces \( P \)\textsubscript{aeruginosa} Gram-negative prosthetic joint infection. A bispecific antibody targeting \( P \)\textsubscript{aeruginosa} PcrV and Psl virulence factors associated with biofilm formation (MEDI3902) (n = 19) or an isotype control human IgG1 monoclonal antibody (Control Ab) (n = 19) was administered via the retro-orbital vein 1 day prior to performing the in vivo \( P \)\textsubscript{aeruginosa}–PJI in vivo model. (A) Mean in vivo BLI signals quantified as maximum flux (photons/s/cm\textsuperscript{2}/steradian) ± SEM. (B and C) Mean CFU ± SEM recovered from tissue samples (B) and implants (C). (D) IgG quantification (\( \mu \)g/ml) of MEDI3902 (n = 14) and Control Ab (n = 14) levels in tissue homogenates obtained on day 5. LOD, limit of detection. *P < 0.05, †P < 0.01, ‡P < 0.001 between indicated groups, as calculated by using the AUC for each animal, with the AUC values then analyzed by a 1-way ANOVA model with heterogeneous within-group variance (A), nonparametric exact Wilcoxon rank-sum test (B and C) or 2-sample Student’s t test (2 tailed) (D) (P values from multiple comparisons were adjusted by step-up Bonferroni method).
systemic effects of the in vivo GN-PJI. For example, the high inoculum of *E. coli* strain 25922 (1 × 10^6 CFU) resulted in increased ex vivo CFU from the tissue samples (1.4 × 10^6 ± 0.5 × 10^6 CFU), yet no mortality. In contrast, *P. aeruginosa* Xen41 at a lower inoculum (1 × 10^4 CFU) resulted in 5-fold fewer ex vivo CFU from the tissue samples (3.3 × 10^4 ± 0.7 × 10^4 CFU).

Finally, to further evaluate the contribution of biofilm-forming activity to induce GN-PJI in vivo, we evaluated whether targeting bacterial factors involved in biofilm formation affected the infection. For these experiments, mice were prophylactically administered a bispecific antibody MEDI3902 against *P. aeruginosa* PcrV and Psl exopolysaccharide (26, 43, 44) prior to performing the in vivo *P. aeruginosa*-PJI model. MEDI3902 resulted in nearly a 10-fold decrease in the in vivo and ex vivo bacterial burden. These findings suggest that PcrV and Psl are important in the pathogenesis of implant-related biofilm infection in an in vivo setting and that they could represent therapeutic targets for PJI and other implant-related biofilm infections caused by *P. aeruginosa*. The specific targeting of PcrV is particularly relevant because the type III secretion system and production of PcrV might be important in the initial bacterial aggregation that facilitates biofilm formation (29, 41). In addition, the exopolysaccharide Psl is involved in the formation of *P. aeruginosa* biofilms in vitro (41), and a prior in vivo study found that a Psl deletion mutant *P. aeruginosa* strain resulted in less biofilm formation on a catheter infection model in vivo (42). Our findings are consistent with the previously reported biofilm-disrupting activity of an anti-Psl antibody in combination with neutrophils in vitro (45). Most importantly, MEDI3902 likely had therapeutic efficacy by targeting both PcrV and Psl in the in vivo GN-PJI model, which extends the previously reported activity of MEDI3902 against other in vivo models of *P. aeruginosa* infections in mice, including pneumonia, thermal injury, and bacteremia (26, 43, 44). Moreover, MEDI3902 had good tissue penetration in this GN-PJI model and, therefore, might be an attractive alternative against infections caused by antibiotic-resistant *P. aeruginosa* strains.

This study was limited in that a simplified implant was used rather than an actual prosthesis implanted in large animal or human PJI. However, this model was based on a previous model of GP-PJI that has been previously validated and is widely accepted in the literature (30–32, 38, 47–49). The original strain of low biofilm-producing *E. coli* (Xen14) was initially chosen for its purported biofilm-producing activity (33) and its bright in vivo BLI signals to noninvasively and longitudinally monitor the infectious course (50, 51). Comparison of in vivo BLI for the high biofilm-producing strain of *E. coli* (25922) with either *E. coli* Xen14 or *P. aeruginosa* Xen41 was not performed because the high biofilm-producing strain was not engineered to possess the bioluminescent lux construct. However, all other evaluated endpoints demonstrated that *P. aeruginosa* Xen41 and *E. coli* 25922 induced similar degrees of infection in the in vivo GN-PJI model, thus making such a comparison between the two strains feasible.

There are several future directions. We provided initial proof-of-concept efficacy data for targeted antibody therapy with MEDI3902 in this mouse model of *P. aeruginosa*-PJI. Additional work will involve evaluating more time points, changes in leukocyte cell infiltrates, and whether there is a therapeutic effect of administering MEDI3902 after the bacterial inoculation. In addition, previous work has shown that an anti-Psl antibody or MEDI3902 used adjunctively with standard of care antibiotics yields enhanced protective activity and bacterial clearance (26, 45). Therefore, we plan on evaluating the potential of MEDI3902 treatment with antibiotics in *P. aeruginosa*-PJI. Furthermore, given the variability in virulence among the *E. coli* strains, different strains of *P. aeruginosa* could also have varying degrees of virulence in this mouse model of GN-PJI. Therefore, we plan on comparing different *P. aeruginosa* clinical isolates and whether MEDI3902 has a similar therapeutic effect. However, it is expected that MEDI3902 will have broad efficacy against other *P. aeruginosa* strains, as we previously demonstrated in other in vivo mouse models of lung infection, thermal injury, and bacteremia (26, 43, 44).

In conclusion, a mouse model of GN-PJI established that *P. aeruginosa* and a high biofilm-producing *E. coli* strain induced a reliable implant-related biofilm infection in vivo, which allowed for insights into the pathogenesis of these infections. This model is unique compared with prior models of GP-PJI (15, 16) and is especially relevant, as GN bacteria are an important and increasingly common cause of PJI in humans (4–9). In addition, the efficacy of the bispecific antibody MEDI3902 in reducing the bacterial burden indicates that PcrV, Psl, or both are important factors in the pathogenesis of an implant-related biofilm infection in vivo and suggests MEDI3902 could be used as a nonantibiotic prophylactic and/or treatment approach. This is highly desirable because MEDI3902 would maintain activity against antibiotic-resistant *P. aeruginosa* strains without increasing the spread of antibiotic resistance or altering the composition of the beneficial microbiota (52). With the increasing incidence of GN-PJI, future studies are warranted to
further investigate GN-PJI in the mouse model presented herein and in other orthopedic implant infections involving larger animal models and humans.

**Methods**

*P. aeruginosa* and *E. coli* strains. Bacteria strains used include *P. aeruginosa* strain Xen41 (parent strain is the well-characterized PAO1 reference strain) and *E. coli* strain Xen14 (parent strain is WS2572, a well-characterized clinical isolate from the Weihenstephan Culture Collection, Munich Technical University) (PerkinElmer) (50), which both produce biofilms in vitro (33). Additional *E. coli* strains that were used include the reference strains 25922 (isolated from a patient in Seattle, Washington, USA, in 1946) (ATCC) and K12 (isolated from a patient stool sample in 1922) (ATCC) as well as 836, an ESBL-producing strain from a patient with a urinary tract infection at the Johns Hopkins Hospital in 2013 (40).

Bacterial preparation. *P. aeruginosa* and *E. coli* strains were streaked onto plates containing Luria-Bertani (LB) broth plus agar (1.5%) (Becton Dickinson). Colonies were grown overnight in LB broth at 37°C with shaking at 240 rpm, followed by 2.5-hour subcultures at 1:50 dilution to obtain midlogarithmic phase bacteria. To determine the optimal inocula for *P. aeruginosa* Xen41 and *E. coli* Xen14 for the in vivo model of GN-PJI (see below), inocula of $1 \times 10^3$, $1 \times 10^4$, and $1 \times 10^5$ CFU were compared (Supplemental Figures 1 and 2); *P. aeruginosa* Xen41 at an inoculum of $1 \times 10^4$ CFU and *E. coli* Xen14 (and strain 25922) at an inoculum of $1 \times 10^5$ CFU were used in subsequent experiments.

**Mice.** Male C57BL/6 mice aged 6–8 weeks (Jackson Laboratories) were used in all experiments. All mice were bred and maintained under specific pathogen–free conditions at an animal facility accredited by the American Association for the Accreditation of Laboratory Animal Care at Johns Hopkins and housed according to procedures described in the *Guide for the Care and Use of Laboratory Animals* (National Academies Press, 2011).

**In vivo model of GN-PJI.** Mice underwent surgical implantation of a Kirschner-wire implant into the right knee joint as previously described (30–32). Briefly, mice were anesthetized with 2% isoflurane, and a medial parapatellar approach was used. The patella was dislocated laterally to gain access to the distal femur. The medullary canal was then reamed retrograde with a 25-gauge needle, and a 0.5 mm × 9 mm titanium Kirschner-wire (Modern Grinding) was inserted in a retrograde fashion into the distal femur. Approximately 0.5 mm was left protruding into the knee joint, onto which was directly pipetted 2 μl of the selected inocula of *P. aeruginosa* or *E. coli* bacteria or sterile PBS for uninfected control mice. The patella was carefully relocated, and the surgical incision was closed using two interrupted absorbable sutures.

**In vivo BLI.** In vivo BLI was performed using an IVIS Lumina III imaging system (PerkinElmer) as previously described (30–32). Imaging was performed immediately before (day 0) and then 1, 3, 7, 14, and 21 days after surgery. Mice were axially rotated within the chamber such that the right (surgical) leg was elevated 45 degrees from the horizontal. Bioluminescence was measured via maximum flux (photons/s/cm²/steradian) obtained over a 5-minute period using large binning within a region of interest of 0.75 cm × 0.5 cm centered over the surgical leg. The LOD was $2.4 \times 10^3$ photons/s/cm²/steradian.

**Ex vivo bacterial quantification.** On day 21, mice were euthanized and tissue samples from the proximal tibia through the midshaft of the femur were harvested and the implants were meticulously extracted as previously described (30–32). Bacterial CFU were isolated from the tissue samples by homogenizing (Pro200 Series homogenizer; Pro Scientific) in PBS on ice. Bacterial CFU were isolated from the implants by vortexing for 2 minutes before and after sonicating the implants in a 0.3% Tween solution (MilliporeSigma) for 10 minutes to dislodge any bacteria embedded within biofilm. Ex vivo CFU were enumerated using QuantityOne (Bio-Rad) after serially diluting the tissue homogenates or sonications and overnight culture on LB plates. All individual colonies were assessed for BLI signals to exclude possible contaminants. To qualitatively determine the presence or absence of bacteria, the original tissue homogenates and sonicated solutions were incubated in LB broth for 48 hours at 37°C with shaking at 240 rpm. Bacterial growth was assessed by visual inspection of turbidity and then overnight culture on LB plates, which were also assessed for BLI signals to exclude possible contaminants.

**Scanning electron microscopy.** Implants were extracted on day 21 from crushed bone so as not to disturb the biofilm at the intra-articular end of the implant and were fixed in buffered 4% formaldehyde and 2.5% glutaraldehyde for 48 hours and rinsed with buffer 3 times (10 minutes each). Secondary fixation was performed for 1 hour in a PBS solution with 1% osmium tetraoxide. Dehydration using increasing levels of ethanol (30%, 50%, 67%, 80%, 90%, and 100% twice) was used for 15 minutes at each step. Implants were then transitioned through an increasing concentration of ethanol to hexamethyldisilazane (HMDS).
(ethanol/HMDS = 3:1, 1:1, 1:3) for 30 minutes each step, followed by pure HMDS for 15 minutes twice. Samples were air dried overnight to completely evaporate the HMDS. Implants were mounted on an aluminum block stub mounts and sputter-coated with gold-palladium. The entire intra-articular surface of the implant samples was imaged under a field emission scanning electron microscope (JSM-6700F FE-SEM; JEOL) at ×160 and ×1,000 magnification. Biofilm formation was deemed present upon visualization of characteristic viscous fibers.

**X-ray imaging.** On day 21, mice were euthanized and anteroposterior radiographs of the surgical knee were obtained using a Faxitron MX-20 (Faxitron Bioptics). Radiographs were then assessed using ImageJ (NIH). Maximum distal femoral width was determined by identifying the widest segment of bone perpendicular to the anatomical axis of the femur that was proximal to the fabella. Femoral length was measured via a line from the intercondylar notch to another line perpendicular to the anatomical axis of the femur that bisects the third trochanter. Distal femoral surface area was then calculated for the outer cortical area of the distal 50% of the femur; patella that were chronically dislocated on radiographs were not included in the overall outer cortical area.

**Histological analysis.** On day 21, mice were euthanized and implants were extracted from the midshaft of the femur so that minimal destruction of the distal aspect of the femur occurred. The knee bone/joint samples were fixed in 4% formalin overnight then decalcified and embedded within paraffin. The paraffin blocks were sectioned sagittally at 4-μm thickness, such that the microtome-cutting plane coincided with maximum anteroposterior diameter of the cylindrical implant. H&E-stained sections were evaluated by light microscopy, and photomicrographs were taken using a Leica DM4000 B LED light microscope mounted with a DFC495 camera (Leica Microsystems).

**PET imaging.** [18F]-FDG PET imaging was performed as previously described (53). Briefly, clinical grade [18F]-FDG was obtained from the Johns Hopkins PET Center Radiopharmacy, supplied by PETNET Solutions (Siemens Healthcare). Injectate was assayed using a sodium iodide CRC-15 dose calibrator and a calibration factor of 439 (Capintec). On day 21, mice were anesthetized with inhalation isoflurane (2%) and injected intravenously via the retro-orbital vein with 200 μCi average activity of tracer diluted to a final volume of 100 μl in isotonic saline. Following a 1-hour uptake period under continuous isoflurane anesthesia, mice were imaged using the MicroPET R4 system (Concorde Microsystems Inc.). Data sets were analyzed using ASIPro VM microPET analysis software (Siemens Preclinical Solutions). Volumes of interest (VOIs) were manually defined around the distal femur, and the percentage of activity per gram of tissue was calculated. In this study, we use the definition: percentage injected activity per gram = ([Activity in distal femur (μCi)/weight of VOI (gram)]/[injected activity (μCi)]) × 100%.

**Flow cytometry.** On day 21, mice were euthanized, and the surgical leg was harvested from the proximal tibia through the midshaft of the femur and the implant was carefully removed. Soft tissue around the distal femur and knee joint was passed through a 40-μm nylon cell strainer to create a single-cell suspension. Cells were pelleted at 376 g at 4°C for 8 minutes and then suspended and washed once in RPMI 1640 (Quality Biological) supplemented with 5% penicillin/streptomycin (Quality Biological) and 10% FBS (MilliporeSigma). Cells were resuspended in FACS buffer (Quality Biologicals) plus 1% BSA (MilliporeSigma) at 5 × 10^7 cells/ml. 100-μl aliquots were stained using anti-mouse antibodies against CD45-VioBlue (Miltenyi Biotec), Ly6G-PE (BD Biosciences), Ly6C-FITC (BD Biosciences), F4/80-PE-Cy7 (BD Biosciences), and CD11b-APC-Cy7 (BD Biosciences). Propidium iodide (Miltenyi Biotec), Ly6C-FITC (BD Biosciences), and CD11b-APC-Cy7 (BD Biosciences) were analyzed using ASIPro VM microPET analysis software (Siemens Preclinical Solutions). Volumes of interest (VOIs) were manually defined around the distal femur, and the percentage of activity per gram of tissue was calculated. In this study, we use the definition: percentage injected activity per gram = ([Activity in distal femur (μCi)/weight of VOI (gram)]/[injected activity (μCi)]) × 100%.

**In vitro microtiter biofilm assay.** The in vitro microtiter biofilm assay was performed according to previously described methods (39). Briefly, the bacterial strains were grown in tryptic soy broth (TSB) for 16 hours with shaking at 240 rpm. The overnight culture was diluted with 1% TSB supplemented with 0.2% glucose, and the bacterial concentration was adjusted to an optical density of 0.1 at 600 nm (OD600). 100 μl of each bacterial strain was added into each well of the round-bottom 96-well microtiter plates (Corning) and incubated at 37°C for 24 hours. Bacterial biofilm formation was measured after 3 washings with ddH2O, staining with crystal violet, 3 additional washings with ddH2O, destaining with acetic acid (30%), and finally reading the OD550. Identical results were obtained in this assay using LB broth.

**In vivo administration of MEDI3902 or Control Abs.** The bispecific antibody MEDI3902, which targets *P. aeruginosa* biofilm-related antigens PcrV and Psl, and a control anti-HIV IgG1 monoclonal antibody (R347) were obtained from MedImmune. MEDI3902 and the R347 Control Ab were diluted in sterile...
PBS to a final concentration of 15 mg/kg and 11.7 mg/kg, respectively (calculated to have the same molecular weight as MEDI3902, which has a molecular weight of 200.3 kDa, whereas control IgG has a molecular weight of 150 kDa) and injected via the retro-orbital vein 1-day prior to performing the in vivo GN-PJI mouse model. For comparison, a sham injection of PBS (saline) was injected intravenously into mice as a no antibody control group.

*Human antibody quantification from tissue homogenates.* The concentration of MEDI3902 and Control Ab (R347) in tissue/bone homogenates was determined by ELISA. The procedure is a heterogeneous format in which wash steps follow after each incubation. All plates were washed 3 times with PBS supplemented with 0.1% Tween20. 96-well plates (NUNC MaxiSorp, ThermoFisher Scientific) were coated with 0.05 ml/well (0.5 mcg/ml) of sheep anti-human IgG (H+L) diluted in carbonate/bicarbonate buffer and incubated overnight at 4°C. Washed plates were blocked with assay buffer (PBS + 1% BSA) for 1 hour at room temperature. Antibodies prepared for the standard curve, quality controls, and samples were diluted appropriately in assay buffer, followed by addition of 0.05 ml to blocked plates. The plates were incubated at room temperature on a 96-well plate shaker at 350 rpm for 2 hours. After incubation, plates were washed followed by the addition of 0.05 ml goat anti-human IgG (H+L)-HRP (1:15,000) and incubated at room temperature with shaking for 30 minutes. Washed plates were developed with SureBlue Reserve (KPL SeraCare) (0.05 ml/well) for 5–15 minutes at room temperature followed by reaction termination with sulfuric acid (0.05 ml/well). Plates were read on a spectrophotometer at 450 nm, and data were analyzed with Soft Max Pro version 5.4 (Molecular Devices). The standard curve was established using a 4-parameter logistical curve fit model without weighting in SoftMax Pro (SMP) software. The nominal range of this assay was 1–1,000 ng/ml.

*Statistics.* Data for longitudinal comparisons were calculated by using the AUC for each animal, and then the AUC values were analyzed by a 1-way ANOVA model with heterogeneous within-group variance. Data for single time point comparisons across multiple groups (≥3 groups) were analyzed by nonparametric Kruskal-Wallis Dunn’s test or a 1-way ANOVA model with heterogeneous within-group variance. For comparison between 2 groups, nonparametric exact Wilcoxon rank-sum test or 2-sample Student’s t test (2 tailed) were performed. Fisher’s exact test was applied for comparison between percentage values of cross tabulations. The specific tests performed are indicated in the figure legends. *P* values from multiple comparisons were adjusted by step-up Bonferroni method to control overall family-wise error rate. Statistical analysis were performed in SAS Studio 3.7 (SAS Institute Inc.), and figures were generated in Prism (GraphPad). Data are presented as mean ± SEM, and values of *P* < 0.05 were considered significant.

*Study approval.* All mice were bred and maintained under specific pathogen–free conditions at an animal facility accredited by the American Association for the Accreditation of Laboratory Animal Care at Johns Hopkins and housed according to procedures described in the *Guide for the Care and Use of Laboratory Animals* (National Academies Press, 2011). All animal studies were approved by the Johns Hopkins University Animal Care and Use Committee.

**Author contributions**

JMT, RJM, AGA, CAD, JEP, YW, RVO, LY, and AD performed experiments and analyzed data. JMT, RJM, RSS, KPF, NMB, TSC, CT, CKS, AD, BRS, DLJT, and LSM conceived the study, designed experiments, interpreted data, and wrote the manuscript.

**Acknowledgments**

This work was supported by grants T32AR07708 (to JMT and JEP) and R01AR073665 and R01AR069502 (to LSM) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases from the US NIH and, in part, by a sponsored research agreement from MedImmune, through a Johns Hopkins-MedImmune Academic Industry Partnership. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH.

Address correspondence to: Lloyd S. Miller, Johns Hopkins Department of Dermatology, Cancer Research Building II, Suite 205, 1550 Orleans Street, Baltimore, Maryland 21231, USA. Phone: 410.955.8662; Email: lloydmiller@jhmi.edu.


